The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

Researchers at ASH shared Phase III data comparing the pre- and five-year posttreatment adjusted annualized bleeding rates, ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

A new analysis presented at ASH found Black AML patients were five years younger, on average, than White patients, and less ...

NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.

A large international analysis found no adverse effect of menopausal hormonal therapy among women with high genetic cancer risks.

The results mark a setback for the hypothesis that drugs like semaglutide could provide a neuroprotective effect for patients ...

The financing comes as the FDA has lifted a clinical hold on the firm's MyPEAK-1 trial testing TN-201 in MYBPC3-associated hypertrophic cardiomyopathy.